Calliditas Therapeutics AB (publ) (CALT) – Analysts’ Weekly Ratings Updates

Calliditas Therapeutics AB (publ) (NASDAQ: CALT) recently received a number of ratings updates from brokerages and research firms:

  • 5/31/2024 – Calliditas Therapeutics AB (publ) had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $39.00 price target on the stock.
  • 5/28/2024 – Calliditas Therapeutics AB (publ) had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.
  • 5/28/2024 – Calliditas Therapeutics AB (publ) was downgraded by analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating.
  • 5/28/2024 – Calliditas Therapeutics AB (publ) had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $39.00 price target on the stock, down previously from $58.00.
  • 5/28/2024 – Calliditas Therapeutics AB (publ) had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $40.00 price target on the stock, down previously from $55.00.
  • 5/24/2024 – Calliditas Therapeutics AB (publ) had its price target lowered by analysts at HC Wainwright from $50.00 to $45.00. They now have a “buy” rating on the stock.

Calliditas Therapeutics AB (publ) Price Performance

NASDAQ:CALT opened at $39.50 on Tuesday. The company has a quick ratio of 2.62, a current ratio of 2.69 and a debt-to-equity ratio of 8.46. The business’s 50-day simple moving average is $24.24 and its two-hundred day simple moving average is $22.83. The stock has a market cap of $1.18 billion, a PE ratio of -21.35 and a beta of 1.77. Calliditas Therapeutics AB has a 52 week low of $15.25 and a 52 week high of $41.90.

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Free Report) last posted its quarterly earnings results on Thursday, May 23rd. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74). The business had revenue of $28.43 million for the quarter, compared to the consensus estimate of $35.78 million. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. As a group, analysts forecast that Calliditas Therapeutics AB will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALTFree Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.

Read More

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.